Glycogen Synthase Kinase 3 Beta (Serine/Threonine Protein Kinase GSK3B or GSK3B or EC 2.7.11.26 or EC 2.7.11.1) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Powered by
All the vital news, analysis, and commentary curated by our industry experts.
Glycogen synthase kinase 3 beta constitutively activate protein kinase that acts as a negative regulator in the hormonal control of glucose homeostasis, Wnt signaling, and regulation of transcription factors and microtubules. The Glycogen Synthase Kinase 3 Beta pipeline drugs market research report outlays comprehensive information on the Glycogen Synthase Kinase 3 Beta (Serine/Threonine Protein Kinase GSK3B or GSK3B or EC 2.7.11.26 or EC 2.7.11.1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also reviews key players involved in Glycogen Synthase Kinase 3 Beta (Serine/Threonine Protein Kinase GSK3B or GSK3B or EC 2.7.11.26 or EC 2.7.11.1) targeted therapeutics development with respective active and dormant or discontinued projects.
GSK3B Pipeline Drugs Market Segmentation by Therapy Areas
The key therapy areas in the GSK3B pipeline drugs market are the central nervous system, oncology, genetic disorders, musculoskeletal disorders, ear nose throat disorders, ophthalmology, and undisclosed.
GSK3B Pipeline Drugs Market Analysis, by Therapy Areas, 2022 (%)
For more GSK3B pipeline drugs therapy area insights, download a free report sample
GSK3B Pipeline Drugs Market Segmentation by Mechanism of Actions
The key mechanism of action in the GSK3B pipeline drugs market is Glycogen Synthase Kinase 3 Beta Inhibitor.
GSK3B Pipeline Drugs Market Segmentation by Routes of Administration
The key routes of administration in the GSK3B pipeline drugs market are oral, intravenous, intratympanic, parenteral, and sublingual.
GSK3B Pipeline Drugs Market Analysis, by Routes of Administration, 2022 (%)
For more GSK3B pipeline drugs routes of administration insights, download a free report sample
GSK3B Pipeline Drugs Market Segmentation by Molecule Types
The key molecule types in the GSK3B pipeline drugs market are small molecule and synthetic peptide.
GSK3B Pipeline Drugs Market Analysis, by Molecule Types, 2022 (%)
For more GSK3B pipeline drugs molecule type insights, download a free report sample
Competitive Landscape
Some of the leading companies in the GSK3B pipeline drugs market are Actuate Therapeutics Inc, Alzamend Neuro Inc, AMO Pharma Ltd, Angelini Spa, Ankar Pharma SL, Avenzoar Pharmaceuticals Inc, CerebraMed, Collaborative Medicinal Development LLC, Frequency Therapeutics Inc, and IGC Pharma LLC.
GSK3B Pipeline Drugs Market Analysis, by Companies, 2022 (%)
To know more about the GSK3B pipeline drugs companies, download a free report sample
Glycogen Synthase Kinase 3 Beta Pipeline Drugs Market Report Overview
Key Therapy Areas | Central Nervous System, Oncology, Genetic Disorders, Musculoskeletal Disorders, Ear Nose Throat Disorders, Ophthalmology, and Undisclosed |
Key Mechanism of Actions | Glycogen Synthase Kinase 3 Beta Inhibitor |
Key Routes of Administration | Oral, Intravenous, Intratympanic, Parenteral, and Sublingual |
Key Molecule Types | Small Molecule and Synthetic Peptide |
Leading Companies | Actuate Therapeutics Inc, Alzamend Neuro Inc, AMO Pharma Ltd, Angelini Spa, Ankar Pharma SL, Avenzoar Pharmaceuticals Inc, CerebraMed, Collaborative Medicinal Development LLC, Frequency Therapeutics Inc, and IGC Pharma LLC |
Segments Covered in the Report
GSK3B Pipeline Drugs Market Therapy Areas Outlook
- Central Nervous System
- Oncology
- Genetic Disorders
- Musculoskeletal Disorders
- Ear Nose Throat Disorders
- Ophthalmology
- Undisclosed
GSK3B Pipeline Drugs Market Mechanism of Actions Outlook
- Glycogen Synthase Kinase 3 Beta Inhibitor
GSK3B Pipeline Drugs Market Routes of Administration Outlook
- Oral
- Intravenous
- Intratympanic
- Parenteral
- Sublingual
GSK3B Pipeline Drugs Market Molecule Types Outlook
- Small Molecule
- Synthetic Peptide
Scope
This report provides:
- A snapshot of the global therapeutic landscape for Glycogen Synthase Kinase 3 Beta (Serine/Threonine Protein Kinase GSK3B or GSK3B or EC 2.7.11.26 or EC 2.7.11.1).
- Reviews of Glycogen Synthase Kinase 3 Beta (Serine/Threonine Protein Kinase GSK3B or GSK3B or EC 2.7.11.26 or EC 2.7.11.1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Pipeline products based on various stages of development ranging from pre-registration to discovery and undisclosed stages.
- Descriptive drug profiles for the pipeline products which includes product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities.
- Reviews of key players involved in Glycogen Synthase Kinase 3 Beta (Serine/Threonine Protein Kinase GSK3B or GSK3B or EC 2.7.11.26 or EC 2.7.11.1) targeted therapeutics and enlists all their major and minor projects.
- Assessment of Glycogen Synthase Kinase 3 Beta (Serine/Threonine Protein Kinase GSK3B or GSK3B or EC 2.7.11.26 or EC 2.7.11.1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type.
- Summaries of all the dormant and discontinued pipeline projects.
- Reviews of the latest news and deals related to Glycogen Synthase Kinase 3 Beta (Serine/Threonine Protein Kinase GSK3B or GSK3B or EC 2.7.11.26 or EC 2.7.11.1) targeted therapeutics.
Reasons to Buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies.
- Identify emerging players with potentially strong product portfolio and create effective counterstrategies to gain competitive advantage.
- Identify and understand the targeted therapy areas and indications for Glycogen Synthase Kinase 3 Beta (Serine/Threonine Protein Kinase GSK3B or GSK3B or EC 2.7.11.26 or EC 2.7.11.1). Identify the use of drugs for target identification and drug repurposing.
- Identify potential new clients or partners in the target demographic.
- Develop strategic initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions effectively by identifying key players and their most promising pipeline therapeutics.
- Devise corrective measures for pipeline projects by understanding Glycogen Synthase Kinase 3 Beta (Serine/Threonine Protein Kinase GSK3B or GSK3B or EC 2.7.11.26 or EC 2.7.11.1) development landscape.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
Alzamend Neuro Inc
AMO Pharma Ltd
Angelini Spa
Ankar Pharma SL
Avenzoar Pharmaceuticals Inc
CerebraMed
Collaborative Medicinal Development LLC
Frequency Therapeutics Inc
IGC Pharma LLC
InnoBioscience LLC
Mercaptor Discoveries Inc
Novosteo Inc
Park of Active Molecules
Recursion Pharmaceuticals Inc
Zovis Pharmaceuticals
Table of Contents
Table
Figures
Frequently asked questions
-
What are the key therapy areas of the GSK3B pipeline drugs market?
The key therapy areas in the GSK3B pipeline drugs market are the central nervous system, oncology, genetic disorders, musculoskeletal disorders, ear nose throat disorders, ophthalmology, and undisclosed.
-
What are the key mechanism of actions in the GSK3B pipeline drugs market?
The mechanism of action in the GSK3B pipeline drugs market is Glycogen Synthase Kinase 3 Beta Inhibitor.
-
What are the key routes of administration in the GSK3B pipeline drugs market?
The key routes of administration in the GSK3B pipeline drugs market are oral, intravenous, intratympanic, parenteral, and sublingual.
-
What are the key molecule types in the GSK3B pipeline drugs market?
The key molecule types in the GSK3B pipeline drugs market are small molecule and synthetic peptide.
-
Which are the key companies in the GSK3B pipeline drugs market?
The key companies in the GSK3B pipeline drugs market are Actuate Therapeutics Inc, Alzamend Neuro Inc, AMO Pharma Ltd, Angelini Spa, Ankar Pharma SL, Avenzoar Pharmaceuticals Inc, CerebraMed, Collaborative Medicinal Development LLC, Frequency Therapeutics Inc, and IGC Pharma LLC.
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.